XNCR
Xencor Inc
NASDAQ · Healthcare · Biotechnology · US
$23.19
+1.49%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$22.75
From 52W high−20.85%
Volume2.01M
Market cap$1.72B
P/E (TTM)—
P/S (TTM)16.4x
Div yield—
Key dataOct 19, 2026
Open
$22.75
From 52W high
−20.85%
Volume
2.01M
Market cap
$1.72B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.8x
P/E (TTM)
—
RSI (14)
39.4
MomentumView details →
1D Return
+1.49%
YTD Return
+48.25%
SummaryUpdated Jun 1, 2026
Xencor, Inc. (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Monrovia, California. The company went public in December 2013 and has established itself as a leader in engineered antibody therapeutics. Xencor specializes in developing innovative treatments for cancer and autoimmune diseases using its proprietary XmAb protein engineering platform, which creates enhanced monoclonal antibodies and cytokines with improved therapeutic properties compared to conventional treatments.
Similar companies
Latest newsMore news →
Xencor announced that it will host a webcast on October 26 to discuss Phase 1 study results for XmAb819 in advanced clear cell renal cell carcinoma.14h agoXencor Inc reported Q2 2026 total revenue of $51.2 million, a 17.4% increase year-over-year, with a net loss of $21.7 million and diluted EPS of -$0.29.76d ago